Anvisa approves new medication to prevent migraine crises

The National Agency of Vigilância Sanitária (Anvisa) approved on Tuesday (8) a new migraine drug in Brazil. Called Aquipta, the remedy has the active principle of atogepant and is indicated for the preventive treatment of adults who have at least four migraine episodes per month.

The authorization extends the alternatives available to patients who often live with seizures of the disease. Unlike medications used only to relieve pain after it begins, the new treatment is aimed at preventing migraine episodes.

According to information released by Anvisa, the atogepant acts by blocking a pathway of the organism related to the transmission of pain. Studies presented in the registration process indicated a significant reduction in the number of days patients have migraines throughout the month.

New oral treatment alternative

Aquipta represents a new preventive oral treatment option for migraine. The application for registration was submitted by AbbVie Pharmaceutical, and the authorization is contained in a resolution published in the Official Journal of the Union.

Anvisa highlighted that preventive treatments are already available, but some of the therapies currently used do not specifically act on mechanisms related to the development of the disease. The new drug therefore expands the possibilities for patients who need preventive seizure control.

The approved indication is intended for adult patients who experience four or more migraine episodes per month.

Migraine affects millions of people

Migraine is a condition characterized by recurrent episodes of headache, usually of moderate to severe intensity. The seizures may also be accompanied by symptoms such as nausea, vomiting and increased sensitivity to light and sounds.

According to the data presented by Anvisa, approximately 15% of the world population suffers from the disease, which can cause important impacts on the professional, social and family routine of patients.

Despite sanitary approval, the use of the medicinal product should occur with medical monitoring, which may evaluate the appropriate indication for each patient.